Cargando…
Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers
BACKGROUND AND INTRODUCTION: SHR6390 is a new developed highly effective and selective small-molecule oral CDK4/6 inhibitor. We aimed to evaluate the effect of food on the pharmacokinetics of SHR6390 tablets. METHODS: In an open-label two-way crossover study, 24 healthy Chinese volunteers were rando...
Autores principales: | Liu, Yan-ping, Hu, Ming-hui, Lin, Ping-ping, Li, Ting, Liu, Shu-qin, Wang, Yu-ya, Li, Shao-rong, Li, Xiang-kun, Wang, Chen-jing, Cao, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167418/ https://www.ncbi.nlm.nih.gov/pubmed/35635717 http://dx.doi.org/10.1007/s40268-022-00390-7 |
Ejemplares similares
-
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
por: Long, Fei, et al.
Publicado: (2019) -
The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021) -
A mass balance study of [(14)C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
por: Zhang, Hua, et al.
Publicado: (2023) -
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
por: Wang, Jiayuan, et al.
Publicado: (2017) -
Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2021)